1.14
+3.64%
Close of 9 Nov 2026, in NOK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hofseth Biocare A
Its shares trade on Oslo Børs under the ticker HBC.OL. It has been listed since 2 December 2011. In the fiscal year to 31 December 2025, it reported revenue of NOK 256.3m and a net loss of NOK 134.9m. At that date it held total assets of NOK 394.3m and shareholders' equity of −NOK 74.8m.
Hofseth Biocare ASA engages in the development, marketing, and sale of biomarine ingredients. The company is headquartered in Alesund, More Og Romsdal. The company went IPO on 2011-12-02. The Company’s business is development, manufacturing, marketing and sale of marine ingredients such as oil, calcium and protein products. Its main products are Salmon protein hydrolysate (ProGo), which is a protein for sports, endurance, and recovery powders; Fresh, all-natural salmon oil (OmeGo) that has a full spectrum of omega fatty acids, including EPA, DHA and DPA, totaling 21 different fatty acids; Calcium bone powder (CalGo) is a natural marine collagenic bone powder and CollaGo is a Collagen Peptide powder optimised to improve the beauty of hair, skin and nails. Hofseth BioCare's headquarters are in Aalesund with branches in Oslo, Chicago, Mumbai, Tokyo and Menlo Park, California.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Dec 2011
- Employees
- 62
- Website
- hofsethbiocare.com ↗
Leadership
Pay as last reported
- Mr. Roger HofsethInterim Chairman of the Board, since 2009NOK 542,000
- Mr. Jon OdegardChief Executive OfficerNOK 1.8m
- Mr. Karl Inge SlotsvikChief Operating Officer
- Dr. Bomi FramrozeChief Scientific OfficerNOK 5.3m
- Mrs. Henriette Godo HeggdalQA/QC Manager, Director, since 2013NOK 856,000
- Mr. James BergerChief Commercial Officer
- Ms. Maria BechDirector
- Dr. Crawford CurrieDirector
- Ms. Linda HoffDirector
- Mr. Christoph BaldeggerIndependent DirectorNOK 56,000
- Ms. Amy NovogratzIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 74
- Environment
- 83
- Social
- 64
- Governance
- 76
- Direct emissions (scope 1)
- 15,025 t
- Energy emissions (scope 2)
- 83,760 t
- Value chain emissions (scope 3)
- 1,127,909 t
- Women in the workforce
- 51.2%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Hofseth Biocare ASA develops marine ingredients like ProGo and OmeGo for health markets.
- The company's products include CalGo calcium powder and CollaGo collagen peptides for beauty.
- Hofseth Biocare has a global presence with branches in Oslo, Chicago, and Tokyo.
Weaknesses
- Hofseth Biocare has only 62 employees, limiting operational scale.
- The company's IPO was in 2011, indicating limited recent capital growth.
- Hofseth Biocare's headquarters are in Alesund, a small city with limited resources.
Opportunities
- Hofseth Biocare can expand its marine ingredient market in Asia with branches in Mumbai and Tokyo.
- The demand for natural omega fatty acids in OmeGo presents growth potential.
- Hofseth Biocare can leverage its biotechnology sector for new product development.
Threats
- Hofseth Biocare faces competition from other biotechnology firms in the Health Care sector.
- The company's reliance on marine ingredients may be affected by environmental changes.
- Hofseth Biocare's small employee count could hinder rapid market response.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.